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Patent ductus arteriosus (PDA) is a congenital heart 
disease defined as the arterial connection between the 
pulmonary artery and the aorta. The ductus arteriosus is 
an essential structure that shunts blood away from the 
lungs during fetal life, and only becomes abnormal if it 
remains patent more than three months after birth in 
term infants. Spontaneous delayed closure of the ductus 
arteriosus occurred in 79% of infants during the neo-
natal period.
1) 
The overall incidence in infants born prematurely is 
about 16 times higher than the incidence in full term in-
fants. The rate of PDA in extremely premature neonates 
is close to 30%. Preterm infants with symptomatic heart 
failure secondary to persistent patency of the ductus ar-
teriosus may be treated by surgical ligation or medically 
with conservative treatment such as indomethacin or ib-
uprofen. Medical intervention is usually the treatment 
of choice due to the risks involved with surgical ligation. 
Early surgical ligation was supported as the optimal th-
erapy for PDA because it ensured definitive ductal clo-
sure with minimal morbidity and mortality in theses 
high risk infants.
1)2)  
Diagnosis of PDA is usually based on clinical examin-
ation and transthoracic echocardiography. Now that co-
lor Doppler imaging has been introduced, it is possible 
to accurately assess even a tiny PDA.
1)3)  
PDAs are usually classified as small, moderate or large 
by size measurement, and as type A (conical ductus), B 
(window like ductus), C (tubular ductus), D (ductus with 
multiple narrowing) or E (elongated ductus) by its con-
figuration on an angiogram of the aortic arch.
3)  
The traditional approach of PDA closure, either with 
surgery or, more recently, with transcatheter techniques, 
has been the mainstay of treatment. And management 
of PDA has continued to progress as innovative tech-
nologies have become available. Thus, the outcome and 
goals for PDA closure have changed and depend on the 
treatment modality. Indeed, strategies for management 
of PDA continue to evolve.   
 
Changing Treatment Modalities   
Over Time and in Association With 
Development of New Devices 
 
After the first successful surgical closure of PDA was 
described in 1939, surgical procedures remained, for se-
veral decades, the only practical tools for closing the duc-
tus.
1)2) At that time, the only goals for treatment were 
to avoid pulmonary overflow and to decrease the risk 
of endocarditis. The next surgical modification occurred 
in 1991, when PDA closure by video-assisted thoracos-
copic surgery was introduced.
4)  
In reviewing catheter interventions for PDA closure, 
Wierny et al.
5) reported the first successful attempt 
using an Ivalon plug to do non-surgical closure in 1971. 
In 1979, Rashkind et al.
6) described successful deploy-
ment of a percutaneously delivered double umbrella de-
vice in an infant with a body weight of only 3.5 kg. Th-
ereafter, several different devices, including buttoned 
devices and stainless steel coils, became readily available 
for the transcatheter occlusion of a PDA. But, they have 
produced varying outcomes.
6-14) Gianturco embolization 
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coils, detachable coils (Cook Cardiology, Bloomington, 
IN, USA), and the Duct-Occlud (Pfm, Cologne, Ger-
many) device have proven both safe and effective in the 
closure of small to moderate-sized PDAs. However, they 
have not been shown to be effective in the transcathe-
ter approach to a large PDA.
2)4)7)9)15) These surgical or ca-
theter-derived techniques became complementary appli-
ed for PDA closure at that time. Percutaneous embo-
lization of coils has been used predominantly for sm-
aller ducts, while larger ones were interrupted by open 
thoracotomy or, occasionally, by video-assisted ligation. 
For the transcatheter closure of moderate to large PDAs, 
Nit-Occlud devices (Pfm, Cologne, Germany), which were 
developed from the original Duct-Occlud device, have 
had relatively favorable outcomes.
10-14) Moreover the Am-
platzer ductal occluder (ADO) device (AGA Medical Cor-
poration, Golden Valley, MN, USA) permitted closure 
of larger ductus, even ones as large as 16/14 mm in dia-
meter since 2003 and showed excellent outcomes.
2)15) 
The management of a silent ductus remains contro-
versial because its risk for endocarditis is low. Transca-
theter therapy for PDA closure is readily available and 
this has prompted physicians to offer elective closure of 
ductus to all patients.
2)11)14)15) 
 
Outcomes and Complication  
of Transcatheter Closure 
of Patent Ductus Arteriosus 
 
Currently, the advent of new technology has increas-
ed the proportion of patients who undergo successful per-
cutaneous closure; there have been only a few of minor 
complications compared with initial interventional data. 
Choi et al.
7) reported comparative results for several 
devices from ‘old’ Sideris and umbrella devices to ‘br-
and-new’ Amplatzer devices. Even though the initial data 
were not remarkable, he showed the historical trends 
and patterns for the selection of devices in transcathe-
ter PDA closure during the past 12 years. After the types 
of devices had evolved, the occlusion rates improved 
and there was an increase in the proportion of patients 
who had good results with transcatheter PDA closure.   
In 1999 Rao et al.
8) reported successful implantation 
of a buttoned device in 278 (98%) of 284 patients. Com-
plete occlusion occurred only in 167 (60%), and a trivial 
shunt in 79 (28%) patients.   
According to serial data with a controlled-release 
Cook coil, immediate and complete angiographic closure 
was achieved in 41%; color Doppler echocardiography 24 
hours after the procedure revealed no detectable shunt 
in 33 of 36 patients (92%).
9) 
In a comparison of occluding coils and the Rashkind 
umbrella device, complete closure was achieved in 89% 
in the coil group as compared to 71% for the Rashkind 
umbrella device group (p<0.005). Eleven coils in six pa-
tients embolized to the pulmonary arteries.
12) 
Trometzki et al.
10) reported that in PDA closure us-
ing Duct-Occlud devices, the devices were successfully 
deployed in 86% of patients; for detachable coils the rate 
was 91%. Embolization of the device occurred on 4 oc-
casions. Two devices were not retrieved but caused no ap-
parent clinical problems.   
Gamboa et al.
11) reported that PDA closures were done 
using Nit-Occlud devices in 28 patients who had a me-
dian age of 1.8 years (range 0.5-21 years) between 2003 
and 2006. The occlusion rate immediately after embo-
lization was 53.5%, which increased to 95.2% by 12 
months and to 100% by 18 months. The Nit-Occlud de-
vice provided an effective and safely retrievable means 
for PDA closure, irrespective of ductus morphology. 
In another study of closure of moderate to large PDAs, 
ADO was compared with Rashkind or Sideris devices 
and Cook detachable coils in 116 consecutive patients.
13) 
In patients receiving an ADO, complete occlusion was 
achieved earlier after implantation, and the rate of com-
plete occlusion was better (97%, p=0.024) than in pa-
tients using other devices.
13) Complications included 
device embolization in 2 patients, hemolysis in 3 patients 
and repeat procedures to retrieve the device in 12 pati-
ents.
13) Recently, transcatheter closure of moderate to large 
PDAs using the ADO showed that the ADO is easily 
retrievable and that the procedure is effective, and safe, 
and provides better results than can be achieved using 
other occluders.
7)15)  
For patients who undergo transcatheter closure with 
devices, the immediate occlusion rates are in excess of 
90% and immediate complication rates are very low. 
There is a potential for left pulmonary artery and de-
scending aortic obstruction in patients who are of low 
weight with a large ductus requiring a relatively large de-
vice for closure, which is rare and normally resolves with 
aging. Since new generation devices, which are easily re-
trievable and have a variety of different sizes, were intro-
duced a few years ago, older devices such as the Rash-
kind double umbrella and the Sideris buttoned device, 
which had a significant risk for retrieval of malposition-
ed devices, are no longer used. Therefore the incidence 
of complications including residual leak, device embo-
lization, protrusion into the aorta, obstruction of left pul-
monary artery, and loss of peripheral pulses, have been 
further decreased, and even the number of these com-
plications gradually decline within 36 months.
10)14) 
The current strategy for transcatheter closure of PDAs 
is to use coils for a small to a moderate ductus, and an 
ADO for a large ductus. The ADO can be recommend-
ed for a large ductus in infants, in young children with 
a ductus diameter >3 mm, and in older children or ad-
ults with a ductus diameter >4 mm. Several coils, in-
cluding the Nit-Occlud, the Gianturco coil, and deta-
chable coils can be used in patients with a small to a  
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moderate sized ductus. Using Gianturco coils or deta-
chable coils is convenient to close small PDAs in small 
infants who weigh less. Using the current strategy, al-
most any PDA can be closed percutaneously without 
complication, regardless of their size and morphology 
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